Literature DB >> 10193666

Neuroprotective effects of nicergoline in immortalized neurons.

M A Sortino1, A Battaglia, F Pamparana, N Carfagna, C Post, P L Canonico.   

Abstract

We studied the potential neuroprotective action of nicergoline in immortalized hypothalamic GT1-7 cells exposed to agents which deplete levels of reduced glutathione, thus causing oxidative stress and cell death. Treatment with diethylmaleate (1 mM), buthionine sulfoximine (500 microM) or menadione (10-50 microM) caused diffuse GT1-7 cell degeneration, as assessed by using either the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay or the fluorescent dyes fluorescein diacetate and propidium iodide. Pre- and/or co-exposure of the cells to nicergoline significantly prevented diethylmaleate- or buthionine sulfoximine-induced neuronal death, whereas nicergoline was ineffective against menadione-induced toxicity. This effect was concentration-dependent and was mimicked by the classical antioxidants idebenone and vitamin E, and did not depend on interference with protein kinase C. Interestingly, the antineurodegenerative activity of nicergoline and vitamin E or idebenone was not additive, suggesting that these compounds share some intracellular mechanism(s) responsible for their protective effects. In conclusion, the present data indicate that nicergoline has neuroprotective activity, possibly mediated by the antioxidant activity of the molecule, and give support to the potential use of nicergoline in the prevention and therapy of neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10193666     DOI: 10.1016/s0014-2999(99)00041-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Changes in Regional Cerebral Perfusion after Nicergoline Treatment in Early Alzheimer's Disease: A Pilot Study.

Authors:  Jooyeon J Im; Hyeonseok S Jeong; Jong-Sik Park; YoungSoon Yang; Seung-Hee Na; Jin Kyoung Oh; Yong-An Chung; In-Uk Song
Journal:  Dement Neurocogn Disord       Date:  2017-12-31

2.  A clinical trial of nicergoline to prevent temporary threshold shift.

Authors:  Pana Klamkam; Rongrat Pagcharoenpol; Treewit Treesaranuwattana; Pichayen Silpsrikul; Pariyanan Jaruchinda; Piyalarp Wasuwat; Picha Suwannahitatorn
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-01-25

Review 3.  Therapeutic use of nicergoline.

Authors:  Bengt Winblad; Mario Fioravanti; Tomas Dolezal; Inara Logina; Ivan Gospodinov Milanov; Dinu Cristian Popescu; Alina Solomon
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 3.580

4.  Online Measurement of Real-Time Cytotoxic Responses Induced by Multi-Component Matrices, such as Natural Products, through Electric Cell-Substrate Impedance Sensing (ECIS).

Authors:  Adyary Fallarero; Ana E Batista-González; Anna K Hiltunen; Jaana Liimatainen; Maarit Karonen; Pia M Vuorela
Journal:  Int J Mol Sci       Date:  2015-11-12       Impact factor: 5.923

Review 5.  A systematic review and meta-analysis assessing adverse event profile and tolerability of nicergoline.

Authors:  Mario Fioravanti; Taku Nakashima; Jun Xu; Amit Garg
Journal:  BMJ Open       Date:  2014-07-30       Impact factor: 2.692

Review 6.  Safety of nicergoline as an agent for management of cognitive function disorders.

Authors:  Bernd Saletu; Amit Garg; Ahsan Shoeb
Journal:  Biomed Res Int       Date:  2014-08-28       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.